Sitagliptin / Metformin hydrochloride Mylan Unión Europea - español - EMA (European Medicines Agency)

sitagliptin / metformin hydrochloride mylan

mylan ireland limited - sitagliptin hydrochloride monohydrate, metformin hydrochloride - diabetes mellitus, tipo 2 - drogas usadas en diabetes - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride mylan is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride mylan is indicated in combination with a sulphonylurea (i. , terapia de combinación triple) como complemento a la dieta y ejercicio en pacientes inadecuadamente controlados en su máxima dosis tolerada de metformina y una sulfonilurea. sitagliptin/metformin hydrochloride mylan is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparg) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparg agonist. sitagliptin/metformin hydrochloride mylan is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

Sitagliptin / Metformin hydrochloride Accord Unión Europea - español - EMA (European Medicines Agency)

sitagliptin / metformin hydrochloride accord

accord healthcare s.l.u. - metformin hydrochloride, sitagliptin hydrochloride monohydrate - diabetes mellitus, tipo 2 - drogas usadas en diabetes - for adult patients with type 2 diabetes mellitus:it is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. it is indicated in combination with a sulphonylurea (i. , terapia de combinación triple) como complemento a la dieta y ejercicio en pacientes inadecuadamente controlados en su máxima dosis tolerada de metformina y una sulfonilurea. it is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparγ agonist. it is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

Sitagliptin / Metformin hydrochloride Sun Unión Europea - español - EMA (European Medicines Agency)

sitagliptin / metformin hydrochloride sun

sun pharmaceutical industries europe b.v. - sitagliptin fumarate, metformin hydrochloride - diabetes mellitus, tipo 2 - drogas usadas en diabetes - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride sun is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride sun is indicated in combination with a sulphonylurea (i. , terapia de combinación triple) como complemento a la dieta y ejercicio en pacientes inadecuadamente controlados en su máxima dosis tolerada de metformina y una sulfonilurea. sitagliptin/metformin hydrochloride sun is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparγ agonist. sitagliptin/metformin hydrochloride sun is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

SITAGLIPTINA/METFORMINA KRKA 50 MG/1000 MG COMPRIMIDOS RECUBIERTOS DE PELICULA EFG España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

sitagliptina/metformina krka 50 mg/1000 mg comprimidos recubiertos de pelicula efg

krka d.d. novo mesto - sitagliptina; metformina hidrocloruro - comprimido recubierto con pelÍcula - 50 mg/1.000 mg - sitagliptina 50 mg; metformina hidrocloruro 1000 mg - metformina y sitagliptina

SITAGLIPTINA/METFORMINA SANDOZ FARMACEUTICA 50MG/1.000 MG COMPRIMIDOS RECUBIERTOS CON PELICULA EFG España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

sitagliptina/metformina sandoz farmaceutica 50mg/1.000 mg comprimidos recubiertos con pelicula efg

sandoz farmaceutica s.a. - sitagliptina hidrocloruro monohidrato; metformina hidrocloruro - comprimido recubierto con pelÍcula - 50 mg/1.000 mg - sitagliptina hidrocloruro monohidrato 50 mg; metformina hidrocloruro 1000 mg - metformina y sitagliptina

SITAGLIPTINA/METFORMINA KERN PHARMA 50 MG/850 MG COMPRIMIDOS RECUBIERTOS CON PELICULA EFG España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

sitagliptina/metformina kern pharma 50 mg/850 mg comprimidos recubiertos con pelicula efg

kern pharma s.l. - sitagliptina hidrocloruro monohidrato; metformina hidrocloruro - comprimido recubierto con pelÍcula - 50 mg/850 mg - sitagliptina hidrocloruro monohidrato 50 mg; metformina hidrocloruro 850 mg - metformina y sitagliptina

SITAGLIPTINA/METFORMINA KERN PHARMA 50 MG/1000 MG COMPRIMIDOS RECUBIERTOS CON PELICULA EFG España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

sitagliptina/metformina kern pharma 50 mg/1000 mg comprimidos recubiertos con pelicula efg

kern pharma s.l. - sitagliptina hidrocloruro monohidrato; metformina hidrocloruro - comprimido recubierto con pelÍcula - 50 mg/1.000 mg - sitagliptina hidrocloruro monohidrato 50 mg; metformina hidrocloruro 1000 mg - metformina y sitagliptina

SITAGLIPTINA/METFORMINA ALTER 50 MG/1000 MG COMPRIMIDOS RECUBIERTOS CON PELICULA EFG España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

sitagliptina/metformina alter 50 mg/1000 mg comprimidos recubiertos con pelicula efg

laboratorios alter s.a. - sitagliptina hidrocloruro monohidrato; metformina hidrocloruro - comprimido recubierto con pelÍcula - 50 mg/1.000 mg - sitagliptina hidrocloruro monohidrato 50 mg; metformina hidrocloruro 1000 mg - metformina y sitagliptina

SITAGLIPTINA/METFORMINA PENSA 50 MG/1.000 MG COMPRIMIDOS RECUBIERTOS CON PELICULA EFG España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

sitagliptina/metformina pensa 50 mg/1.000 mg comprimidos recubiertos con pelicula efg

towa pharmaceutical s.a. - sitagliptina hidrocloruro monohidrato; metformina hidrocloruro - comprimido recubierto con pelÍcula - 50 mg/850 mg - sitagliptina hidrocloruro monohidrato 50 mg; metformina hidrocloruro 850 mg - metformina y sitagliptina

SITAGLIPTINA/METFORMINA ALMUS 50 MG /1000 MG COMPRIMIDOS RECUBIERTOS CON PELICULA EFG España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

sitagliptina/metformina almus 50 mg /1000 mg comprimidos recubiertos con pelicula efg

almus farmaceutica s.a.u. - sitagliptina hidrocloruro monohidrato; metformina hidrocloruro - comprimido recubierto con pelÍcula - 50 mg/1.000 mg - sitagliptina hidrocloruro monohidrato 50 mg; metformina hidrocloruro 1000 mg - metformina y sitagliptina